Vivitra

HER2-overexpressing metastatic breast cancer. In combination w/ an aromatase inhibitor for HER2-overexpressing & hormone receptor +ve metastatic breast cancer. HER2-overexpressing early breast cancer following surgery, chemotherapy (neo-adjuvant or adjuvant) & RT. Adjuvant treatment in HER2-overexpressing node +ve or node -ve breast cancer in combination w/ doxorubicin, cyclophosphamide & either paclitaxel or docetaxel; or w/ docetaxel & carboplatin. HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination w/ capecitabine or 5-FU & cisplatin in patients who have not received prior anti-cancer treatment.

IV infusion Wkly cycle: Loading dose of 4 mg/kg over 90 min. Subsequent dose: 2 mg/kg over 30 min. 3-wkly cycle: Loading dose of 8 mg/kg over 90 min. Subsequent dose: 6 mg/kg over 30 min.

Hypersensitivity.

Discontinue use in acute serious resp disorders eg, dyspnea, hypotension, asthma, bronchospasm, tachycardia, reduced O₂ saturation & resp distress indications.

Anaemia, neutropenia, thrombocytopenia, CHF, left ventricular dysfunction, diarrhoea, nausea, stomatitis, vomiting, asthenia, pyrexia.

Targeted Cancer Therapy

L01FD01 - trastuzumab ; Belongs to the class of HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Used in the treatment of cancer.

K